Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy
Angioplasty, Balloon, Coronary
Coronary Artery Disease
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
The combination of stenting and abciximab therapy among diabetics resulted in a significant reduction in 6-month rates of death, MI, and TVR compared with stent-placebo or balloon-abciximab therapy.